More than 45 organizations, including the American Hospital Association, last week sent a letter to members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act, or the CREATES Act (S. 974), which the panel is expected to consider later this week.
The legislation, cosponsored by several members of the Senate Judiciary Committee, promotes generic drug competition by making it easier for medicines whose patents have expired to be sold as less expensive generic versions. The CREATES Act would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. It is estimated that enacting the CREATES Act would save $3.8 billion over 10 years.
